supCD7 CAR-T cells

supCD7 CAR-T cells represent a specialized form of Chimeric Antigen Receptor (CAR) T-cell therapy designed to target the CD7 protein, which is highly expressed in various T-cell malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and certain peripheral T-cell lymphomas. The 'sup' prefix in supCD7 refers to strategies employed to suppress fratricide, a significant challenge in CD7-targeted CAR-T cell therapy. Fratricide occurs because CAR-T cells themselves express CD7, leading to self-targeting and impaired expansion and function. To overcome this, supCD7 CAR-T cells are engineered using methods like genomic disruption (e.g., CRISPR/Cas9 gene editing) of the CD7 gene within the CAR-T cells, or by utilizing protein expression blockers (PEBL) to prevent CD7 from being expressed on the CAR-T cell surface. Another approach involves expanding the CAR-T cells in the presence of pharmacologic inhibitors of tyrosine kinases. This engineering allows the CAR-T cells to effectively target and eliminate CD7-positive malignant cells without attacking each other, thereby enhancing their anti-tumor efficacy. The therapy involves collecting T cells, genetically modifying them ex-vivo to express the CD7-specific CAR and incorporate fratricide-suppression mechanisms, expanding them, and then infusing them back into the patient.

Other names

CD7 CAR-T cellsCD-7 CAR-T cellsCD 7 CAR-T cellsCD7-edited T cellsCD-7-edited T cellsCD 7-edited T cellsCD7-targeting CAR-T cellsCD-7-targeting CAR-T cellsCD 7-targeting CAR-T cells